Akoya Biosciences Inc (NAS:AKYA)
$ 2.15 -0.04 (-1.83%) Market Cap: 106.57 Mil Enterprise Value: 157.57 Mil PE Ratio: 0 PB Ratio: 7.68 GF Score: 43/100

Akoya Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 02:10PM GMT
Release Date Price: $4.34 (-6.26%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Hey, everyone. I'm Tejas Savant, and I cover the Life Science Tools and Diagnostics sector here at Morgan Stanley. Before we begin, for important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, do reach out to your Morgan Stanley sales rep. So it's my pleasure this morning to host Akoya, and speaking on behalf of the company, we have Brian McKelligon, CEO, and John Ek, CFO. Thank you, both, gents, for doing this.

Questions & Answers

Tejas Rajeev Savant;Brian McKelligon
Morgan Stanley, Research Division - Equity Analyst;Akoya Biosciences,

Maybe, Brian, just to set the stage, you recently achieved the 1,000th instrument milestone. Can you take a few minutes to just recap your approach to spatial biology. How does it differ from other players in the market? And why that's a good thing and highlight some of the achievements that you're most proud of (inaudible).

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot